A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy

Alessandro Fiocchi¹, Bryan Martin², Gary Wing-Kin Wong³, Motohiro Ebisawa⁴, Lucia Lo Scalzo¹, Francesca Galletta⁵, Stefania Arasi¹, Ignacio J Ansotegui⁶, Maryam Ali Al-Nesf Al-Mansouri⁷, Sandra N Gónzalez Díaz⁸, Jonathan A Bernstein^{9

10}, Elham Hossny¹¹, Hiroshi Chantaphakul¹², Luciana K Tanno^{13

14

15}, Tinatin Chikovani¹⁶, David M Lang¹⁷, Luz Fonacier¹⁸, Hideaki Morita¹⁹, Mary Beth Fasano²⁰, José Antonio Ortega-Martell²¹, Pedro Giavina-Bianchi²², Nikolaos G Papadopoulos^{23

24}, R Maximiliano Gómez²⁵, Mário Morais Almeida²⁶

Affiliations

¹ Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
² Medicine and Pediatrics, The Ohio State University in Columbus, Columbus, OH, USA.
³ The Chinese University of Hong Kong, Hong Kong, Special Administrative Region of China.
⁴ Sagamihara National Hospital, Sagamihara, Japan.
⁵ Pediatric Unit, Department of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, Messina, Italy.
⁶ Hospital Quironsalud Bizkaia, Bilbao, Spain.
⁷ Allergy and Immunology Division, Hamad General Hosptial, Hamad Medical Corporation, Doha, Qatar.
⁸ Autonomous University of Nuevo León, Hospital Universitario, Centro Regional de Alergia e Inmunología, Monterrey, Mexico.
⁹ Division of Immunology/Allergy Section, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
¹⁰ Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA.
¹¹ Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.
¹² Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok Thailand.
¹³ Division of Allergy, Department of Pulmonology, Allergy and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.
¹⁴ Desbrest Institute of Epidemiology and Public Health, UMR UA11 University of Montpellier-INSERM, Montpellier, France.
¹⁵ WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.
¹⁶ Tbilisi State Medical University, Tblisi, Georgia.
¹⁷ Cleveland Clinic, Cleveland, OH, USA.
¹⁸ NYU Grossman Long Island School of Medicine, New York, NY, USA.
¹⁹ National Research Insittute for Child Health and Development, Tokyo, Japan.
²⁰ University of Iowa Health Care, Iowa City, IA, USA.
²¹ Universidad Autónoma del Estado de Hidalgo, Pachuca, Hidalgo, Mexico.
²² Clinical Immunology and Allergy Division, University of Sao Paulo, Brazil.
²³ Allergy Department, Second Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
²⁴ Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.
²⁵ Faculty of Health Sciences, Catholic University of Salta, Argentina.
²⁶ Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.

PMID: 41036297
PMCID: PMC12482619
DOI: 10.1016/j.waojou.2025.101113

Editorial

A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy

Alessandro Fiocchi et al. World Allergy Organ J. 2025.

. 2025 Sep 20;18(10):101113.

doi: 10.1016/j.waojou.2025.101113. eCollection 2025 Oct.

Authors

Affiliations

¹ Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
² Medicine and Pediatrics, The Ohio State University in Columbus, Columbus, OH, USA.
³ The Chinese University of Hong Kong, Hong Kong, Special Administrative Region of China.
⁴ Sagamihara National Hospital, Sagamihara, Japan.
⁵ Pediatric Unit, Department of Human Pathology of Adult and Childhood Gaetano Barresi, University of Messina, Messina, Italy.
⁶ Hospital Quironsalud Bizkaia, Bilbao, Spain.
⁷ Allergy and Immunology Division, Hamad General Hosptial, Hamad Medical Corporation, Doha, Qatar.
⁸ Autonomous University of Nuevo León, Hospital Universitario, Centro Regional de Alergia e Inmunología, Monterrey, Mexico.
⁹ Division of Immunology/Allergy Section, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
¹⁰ Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA.
¹¹ Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.
¹² Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok Thailand.
¹³ Division of Allergy, Department of Pulmonology, Allergy and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.
¹⁴ Desbrest Institute of Epidemiology and Public Health, UMR UA11 University of Montpellier-INSERM, Montpellier, France.
¹⁵ WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.
¹⁶ Tbilisi State Medical University, Tblisi, Georgia.
¹⁷ Cleveland Clinic, Cleveland, OH, USA.
¹⁸ NYU Grossman Long Island School of Medicine, New York, NY, USA.
¹⁹ National Research Insittute for Child Health and Development, Tokyo, Japan.
²⁰ University of Iowa Health Care, Iowa City, IA, USA.
²¹ Universidad Autónoma del Estado de Hidalgo, Pachuca, Hidalgo, Mexico.
²² Clinical Immunology and Allergy Division, University of Sao Paulo, Brazil.
²³ Allergy Department, Second Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
²⁴ Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.
²⁵ Faculty of Health Sciences, Catholic University of Salta, Argentina.
²⁶ Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal.

PMID: 41036297
PMCID: PMC12482619
DOI: 10.1016/j.waojou.2025.101113

No abstract available

Keywords: Anaphylaxis; Biological therapies; Biologics; Drug approval process; Epidemiology; Food hypersensitivity.

PubMed Disclaimer

Conflict of interest statement

AF has received Speaker honoraria and advisory panel consultancy outside the submitted work for Nutricia, Abbott, Danone, Stallergenes, DBV, Novartis. Funded research (Institution) from Sanofi, Novartis, Ferrero, DBV, GSK, Astrazeneca, Hipp GmBDH, Humana SpA. IJA reports personal fees from Bayer, Bial, Cipla, Eurodrug, Faes Farma, Gebro, Glenmark, Opella, Menarini, MSD, Roxall and Sanofi outside the submitted work. SA declares that she has participated as an advisory board member, and/or consultant, and/or speaker/chair at scientific meetings for Aimmune, DBV, Ferrero, Mabylon, Novartis, Stallergenes Greer, Thermo Fisher Scientific and Ulrich outside the submitted work. Funded research (Institution) from Italian Minister of Health and Italian Minister of Education. BM declares Speaker honorarium and advisory panel consultancy from Sanofi and Merck. ME reports personal fees from Viatris and SAB of ARS-Pharmaceuticals, Novartis, and Sanofi outside the submitted work. PGB declares speaker honoraria from Novartis. DML reports that he has served as a consultant for, carried out clinical research with, and/or has received honoraria from: AstraZeneca, Celldex, Genentech, Novartis, Sanofi-Regeneron. LF has participated in the advisory board and/or consultant/speaker or received research grant paid to NYU Grossman Long Island School of Medicine from Regeneron, Sanofi, AstraZeneca, Dermavant, Blueprint. NGP reports that he has served as a consultant for, carried out clinical research with, received grants from, and/or has received honoraria from: Abbott Nutrition, Berlin – Chemie AG, Danone, DBV Technologies, GSK, HAL Allergy, Hyproca Nutrition, MED Maps SRL, Menarini, Nestle Nutrition Institute, Numil, Regneron, Vianex, Vibrant America. JB reports grants or contracts from Allakos, Areteia, AstraZeneca, Astria, Celldex, Evoimmune, Genentech, Incyte/Escient, Intellia, IONIS, Jasper, Novartis, Pharvaris, Springer, TLL, and Yuhan; royalties from Amgen, Cogent Pharmaceuticals, CRC Press, and UpToDate; consulting fees from Advanced Medical, Areteia, AstraZeneca, Astria, Best Doctor/Teledoc, BMJ, Celldex, DBV, Eli Lilly, Elsevier, Escient, Evoimmune, Genentech, Guidepoint, GUF, Imedics, Incyte/Escient, INEOS, Intellia, IONIS, Jasper, Kenvue, Novartis, Pharvaris, Telios, TEVA, and Yuhan; and speaking fees from Jasper. HM reports consulting/advisory board agreements with Sanofi, LEO Pharma, and Otsuka Pharmaceutical Co., Ltd. MMA reports personal fees from Astrazeneca, Bayer, Eurodrugs, FAES Farma, GSK, Menarini, MSD, OM Pharma, Sanofi and Viatris, outside the submitted work. All other authors have no conflict of interest within the scope of the submitted work.

References

1. Wood R.A., Togias A., Sicherer S.H., et al. Omalizumab for the treatment of multiple food allergies. N Engl J Med. 2024;390:889–899. - PMC - PubMed
1. Casale T.B., Fiocchi A., Greenhawt M. A practical guide for implementing omalizumab therapy for food allergy. J Allergy Clin Immunol. 2024;153:1510–1517. - PubMed
1. Dantzer J.A., Wood R.A. Anti-IgE and food allergy. J Allergy Clin Immunol. 2025;155:1–11. - PubMed
1. Shaker M.S., Schwartz J., Ferguson M. An update on the impact of food allergy on anxiety and quality of life. Curr Opin Pediatr. 2017;29:497–502. - PubMed
1. Tanno L.K., Worm M., Ebisawa M., et al. WAO Anaphylaxis Committee and the WAO Junior Members Steering Group Global disparities in availability of epinephrine auto-injectors. World Allergy Organ J. 2023;16 - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy

Affiliations

A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy

Authors

Affiliations

Conflict of interest statement

References

Publication types

LinkOut - more resources

Full Text Sources